Shant Thomassian

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “Phase I trial of Bermekimab with nanoliposomal irinotecan and 5-fluorouracil/folinic acid in advanced pancreatic ductal adenocarcinoma”.

Phase I trial of Bermekimab with nanoliposomal irinotecan and 5-fluorouracil/folinic acid in advanced pancreatic ductal adenocarcinoma

Scientific Reports(2022)10.1038/s41598-022-19401-3

N/A

0.587DataRank · unranked

10 citations

Shant Thomassian, Sungjin Kim, Gillian Gresham, Natalie Moshayedi, Jason Ye +9 more

Author Correction: Phase I trial of Bermekimab with nanoliposomal irinotecan and 5‑fuorouracil/folinic acid in advanced pancreatic ductal adenocarcinoma

Scientific Reports(2022)10.1038/s41598-022-23619-6

N/A

0DataRank · unranked

1 citations

Shant Thomassian, Sungjin Kim, Gillian Gresham, Natalie Moshayedi, Jason Ye +9 more